Health
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois. Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZN
About this update from Phathom Pharmaceuticals, Inc.
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois. Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZNA® (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) approved for Gastroesophageal Reflux Disease (GERD), on Monday, May 4 at 12:00 PM CDT, along with a presence on the exhibit floor at booth number 2511. The company will also present clinical and real-world data further characterizing the use of VOQUEZNA across three poster presentations. “We look forward to engaging with the GI community at DDW and building on the progress we have made with VOQUEZNA. The data we are presenting this year spans clinical research, patient-reported outcomes, and real-world evidence, reflecting our continued commitment to advancing the treatment of patients with GERD,” said Steve Basta, President and Chief Executive Officer of Phathom. “DDW provides an important platform to share these insights, connect with experts, and continue strengthening our position in GI.” Following the conclusion of DDW, poster abstracts will be available on Phathom’s publications and scientific section of the company website at www.phathompharma.com/publications/. About VOQUEZNAINDICATIONS AND USAGEVOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information. WARNINGS AND PRECAUTIONS Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an ...
View stock analysis, news, and events for Phathom Pharmaceuticals, Inc.